QUESTIONS
Thymosin Alpha-1: common questions, answered
Direct, cited answers to what people ask most about the thymic immunomodulator.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus as part of thymosin fraction 5; Goldstein and colleagues purified it and determined its complete sequence in 1977 [1]. It is an immune-modulating peptide cleaved in the body from the larger precursor prothymosin alpha.
What does thymosin alpha 1 do?
It tunes the immune system. Signaling through Toll-like receptors (TLR2/TLR9) on dendritic cells, it promotes their maturation and antigen presentation, drives T-cell maturation and a Th1 response, and in parallel activates an IDO-dependent regulatory arm that generates regulatory T cells [5]. The effect is dual: restore effector immunity where it is weak, restrain it where it is excessive.
What is TA1 peptide?
TA1 (also written Tα1) is shorthand for thymosin alpha-1, the 28-amino-acid thymic immunomodulatory peptide [1]. Its synthetic, sequence-identical drug form is named thymalfasin. The label refers to the same molecule whether written as TA1, Tα1, thymalfasin, or thymosin alpha-1.
Is TB-500 the same as thymosin alpha 1?
No. TB-500 is a fragment of thymosin beta-4, a separate 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Thymosin alpha-1 is a different 28-amino-acid immune-signaling peptide [1]. Different sequence, different size, different mechanism, different use — and it is thymosin beta-4, not alpha-1, that is WADA-prohibited.
Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?
They are distinct molecules. Thymosin alpha-1 (28 amino acids) is an immunomodulator that signals through dendritic-cell TLRs to retune immunity [5]. Thymosin beta-4 (43 amino acids), source of TB-500, is an actin-binding peptide acting on cell migration and tissue repair. On a gel they resolve as separate bands at separate weights; only thymosin beta-4 sits in the WADA-prohibited category.
Where does thymosin alpha 1 come from in the body?
It is endogenous. Thymosin alpha-1 is cleaved in the body from a 113-amino-acid precursor protein called prothymosin alpha, and it is associated with the thymus gland [1]. It was first purified from calf thymus tissue. Circulating levels decline with age and are reduced in some chronic inflammatory and autoimmune conditions.
Is thymosin alpha 1 a steroid?
No. Thymosin alpha-1 is a peptide — a 28-amino-acid chain of protein building blocks — not a steroid hormone [1]. It does not act through steroid receptors and has no anabolic or androgenic activity. Its action is immunomodulatory, working through immune-cell receptors rather than the pathways steroids use.
Does thymosin alpha 1 boost the immune system?
It modulates rather than simply boosts. It promotes dendritic-cell maturation, Th1 polarization, and cytotoxic T-cell activity while also generating regulatory T cells through an IDO-dependent arm [5]. In severe COVID-19 it increased T-cell numbers and reversed T-cell exhaustion [6]. The honest framing is a two-way tuning effect, not a one-directional boost.
What are the benefits of thymosin alpha 1?
In the literature the clearest benefits are in chronic hepatitis B, where combination therapy raised HBeAg seroconversion to 45.1% versus 15.2% [10], and as an immune-restorative adjunct. Community members anecdotally report fewer or shorter colds and faster recovery when run-down — impressions, not measured outcomes, covered on the effects page.
What is thymosin alpha 1 used for?
Abroad it is used chiefly for chronic hepatitis B and as an immune adjuvant, and it has been studied in sepsis, severe COVID-19, and as a cancer adjuvant. A reappraisal positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, acting through dendritic cells and the adaptive immune response [14].
Is thymosin alpha 1 FDA-approved?
No. Thymosin alpha-1 (thymalfasin) is not approved for marketing in the United States. It is approved as a drug in roughly 35 other countries, chiefly for hepatitis B and immune support [4]. In the US, availability is limited to investigational and compounding contexts; some historical orphan-drug designations existed but are not marketing approvals.
Who should not take thymosin alpha 1?
The literature raises theoretical caution for people with established autoimmune disease (an immunostimulant broadly enhancing effector immunity) [16] and for solid-organ transplant recipients (it could work against intentional immunosuppression) [5]. Pregnancy and lactation data are absent [4]. These are reasons for caution, not clinical findings, and this site gives no medical advice.
How long should you take thymosin alpha 1?
Trial durations varied by indication: twice-weekly courses over months in chronic hepatitis B, intensive 5-to-7-day regimens in sepsis, and daily dosing in COVID-19 cohorts [4][3]. These are study protocols in specific patient populations, not guidance. This site reports what was studied and does not recommend any duration of use.
How long does it take for thymosin alpha 1 to work?
There is no defined consumer onset; effects in trials are measured as clinical endpoints over weeks, not as a felt sensation. Pharmacokinetically, a subcutaneous dose peaks in blood within about one to two hours with a roughly two-hour elimination half-life [4]. Any immunological change is biochemical and tracked by lab markers, not by how a person feels.
What is the dosing protocol for thymosin alpha 1?
Across the literature, single subcutaneous doses ranged from 0.8 to 6.4 mg, with multiple-dose regimens of 1.6 to 16 mg over five to seven days; the standard hepatitis regimen was 1.6 mg subcutaneous twice weekly [4]. These are study parameters by population and route, reported here for accuracy — not a protocol for any individual to follow.
How does thymosin alpha 1 make you feel?
Most people report feeling nothing in particular, which is expected for an immune modulator whose effects are biochemical rather than perceptible [4]. Anecdotally, some describe a vague sense of resilience or steadier energy during recovery; a minority note a transient flu-like day or injection-site irritation. These are reports, not measured effects — see the effects page.
How much thymosin alpha 1 should I take?
This site does not advise any amount. For context only, studies used single subcutaneous doses of 0.8 to 6.4 mg and a typical 1.6 mg twice-weekly regimen in specified patient populations [4]. Those are research parameters, not recommendations. Decisions about any unapproved peptide should involve a qualified clinician, not a website.
When is the best time to take thymosin alpha 1?
The literature does not establish an optimal time of day; trial protocols specified frequency (for example, twice weekly or every 12 hours) rather than a particular hour [4][2]. Because this is an immunomodulator dosed by clinical schedule in studies, there is no evidence-based 'best time,' and this site offers no timing guidance.
Is thymosin alpha 1 safe to take?
In studied clinical settings it is generally well tolerated; large post-marketing surveillance identifies mild injection-site reactions and occasional transient flu-like symptoms as the dominant adverse events, with no documented organ toxicity at studied doses [17]. Separately, unregulated research-grade material carries identity, purity, and sterility risks [4]. This is not a safety endorsement of unapproved personal use.
Does thymosin alpha 1 help cancer?
It is studied as an adjuvant, not a cure. A reappraisal frames it as an immunostimulatory add-on to chemo- and immunotherapy that may help turn a cold tumour hot and reduce checkpoint-inhibitor toxicity [14]; mechanistically it blocked myeloid-derived suppressor cells in lung cancer by inhibiting VEGF [12]. Evidence is supportive but combination-context and not a standalone treatment claim.
Is thymosin alpha 1 worth it?
That depends on setting and cannot be answered as personal advice. The strongest evidence is in chronic viral hepatitis; the largest, most rigorous sepsis trial was null (hazard ratio 0.99, P=0.93) [3]. Combined with its US non-approval and research-grade quality concerns, the honest summary is: real but qualified evidence, strongest in specific indications.
Does thymosin affect aging?
Circulating thymosin alpha-1 levels decline with age, and immune decline (immunosenescence) is the rationale behind vaccine-adjuvant research with the peptide [1]. But no trial shows it slows aging itself; the studied benefits are immunological, in defined disease settings. Claims that it is an anti-aging therapy go beyond what the evidence supports.